Mast Energy Developments PLC
(Incorporated in England and Wales)
(Registration Number: 12886458)
LEI :213800HFVHGJ9YGO9F71
Share code on the LSE: MAST
ISIN: GB00BMBSCV12
('MED' or 'the Company')
Dated: 2 January 2024
Mast Energy Developments PLC ('MED' or 'the Company')
MED Binding Joint Venture Agreement Completion Update
Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, announces further to its previous RNS dated 22 December 2023, based on the most recent written assurance from Proventure as well as its funders, Proventure will initiate transfer of a first £1m payment to the Project SPV by no later than 4pm US-time on 29 December 2023. Due to the aforementioned deadline being after close of business UK-time on the 29th of December 2023 and given the recent New Year's Day banking holiday long weekend MED has to date not received any formal update from Proventure regarding the status of the aforementioned payment. The Company has now formally engaged with Proventure on this matter, given that today was the first opportunity to do so and is awaiting their response. A further update will be provided to the market as soon as possible.
ENDS
This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.
For further information please visit www.med.energy or contact:
Pieter Krügel | Mast Energy Developments PLC | CEO | |
Jon Belliss | +44 (0)20 7399 9425 | Novum Securities | Corporate Broker |
Zainab Slemang van Rijmenant | Lifa Communications | Investor & Media Relations Advisor |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.